全文获取类型
收费全文 | 12063篇 |
免费 | 1021篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 91篇 |
儿科学 | 286篇 |
妇产科学 | 188篇 |
基础医学 | 1729篇 |
口腔科学 | 196篇 |
临床医学 | 1452篇 |
内科学 | 2515篇 |
皮肤病学 | 385篇 |
神经病学 | 1135篇 |
特种医学 | 433篇 |
外国民族医学 | 2篇 |
外科学 | 1378篇 |
综合类 | 167篇 |
一般理论 | 15篇 |
预防医学 | 1210篇 |
眼科学 | 276篇 |
药学 | 989篇 |
中国医学 | 21篇 |
肿瘤学 | 641篇 |
出版年
2023年 | 55篇 |
2022年 | 90篇 |
2021年 | 266篇 |
2020年 | 175篇 |
2019年 | 231篇 |
2018年 | 281篇 |
2017年 | 205篇 |
2016年 | 229篇 |
2015年 | 258篇 |
2014年 | 321篇 |
2013年 | 480篇 |
2012年 | 696篇 |
2011年 | 718篇 |
2010年 | 408篇 |
2009年 | 361篇 |
2008年 | 614篇 |
2007年 | 642篇 |
2006年 | 607篇 |
2005年 | 658篇 |
2004年 | 639篇 |
2003年 | 557篇 |
2002年 | 528篇 |
2001年 | 331篇 |
2000年 | 346篇 |
1999年 | 260篇 |
1998年 | 150篇 |
1997年 | 104篇 |
1996年 | 108篇 |
1995年 | 101篇 |
1994年 | 79篇 |
1993年 | 61篇 |
1992年 | 203篇 |
1991年 | 180篇 |
1990年 | 190篇 |
1989年 | 197篇 |
1988年 | 168篇 |
1987年 | 150篇 |
1986年 | 147篇 |
1985年 | 119篇 |
1984年 | 107篇 |
1983年 | 82篇 |
1982年 | 62篇 |
1981年 | 56篇 |
1979年 | 85篇 |
1978年 | 67篇 |
1977年 | 70篇 |
1975年 | 61篇 |
1974年 | 51篇 |
1973年 | 68篇 |
1972年 | 53篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Paul J. Devlin Brian W. McCrindle James K. Kirklin Eugene H. Blackstone William M. DeCampli Christopher A. Caldarone Ali Dodge-Khatami Pirooz Eghtesady James M. Meza Peter J. Gruber Kristine J. Guleserian Bahaaladin Alsoufi Linda M. Lambert James E. OBrien Erle H. Austin Jeffrey P. Jacobs Tara Karamlou 《The Journal of thoracic and cardiovascular surgery》2019,157(2):684-695.e8
Objective
Arch obstruction after the Norwood procedure is common and contributes to mortality. We determined the prevalence, associated factors, and practice variability of arch reintervention and assessed whether arch reintervention is associated with mortality.Methods
From 2005 to 2017, 593 neonates in the Congenital Heart Surgeons' Society Critical Left Heart Obstruction cohort underwent a Norwood procedure. Median follow-up was 3.7 years. Multivariable parametric models, including a modulated renewal analysis, were performed.Results
Of the 593 neonates, 146 (25%) underwent 218 reinterventions for arch obstruction after the Norwood procedure: catheter-based (n = 168) or surgical (n = 50) at a median age of 4.3 months (quartile 1-quartile 3, 2.6-5.7). Interdigitation of the distal aortic anastomosis was protective against arch reintervention. Development of ≥ moderate tricuspid valve regurgitation and right ventricular dysfunction at any point was associated with arch reintervention. Nonsignificant variables for arch reintervention included shunt type and preoperative aortic measurements. Surgical arch reintervention was protective against arch reintervention, but transcatheter reintervention was associated with increased reintervention. Arch reintervention was not associated with increased mortality. There was wide institutional variation in incidence of arch reintervention (range, 0-40 reinterventions per 100 years patient follow-up) and in preintervention gradient (range, 0-64 mm Hg).Conclusions
Interdigitation of the distal aortic anastomosis during the Norwood procedure decreased the risk of arch reintervention. Surgical arch reintervention is more definitive than transcatheter. Arch reintervention after the Norwood procedure is not associated with increased mortality. Serial surveillance for arch obstruction, integrated with changes in right ventricular function and tricuspid valve regurgitation, is recommended after the Norwood procedure to improve outcomes. 相似文献4.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
5.
6.
7.
The MMPI was administered during the patient-perceived best time of the menstrual cycle and during the patient-perceived worst time of the cycle in order to examine the stability of MMPI profile configurations. Subjects were 214 women who were referred to two metropolitan outpatient premenstrual syndrome (PMS) clinics for moderate to severe premenstrual complaints. This sample was selected from 1,849 intake files after screening by strict selection criteria for PMS. The results indicate that there are wide fluctuations in profile patterns between the best and worst times of the menstrual cycle for a large number of patients. Caution in using the MMPI is strongly advised. 相似文献
8.
9.
The present study reports the differential effects of pertussis toxin on muscarinic regulation of intracellular Ca2+ and inositol phosphate generation and alpha 2-adrenoceptor-mediated inhibition of cAMP formation in SH-SY5Y human neuroblastoma cells. Carbachol caused a biphasic increase in intracellular Ca2+ (release of internal stores and Ca2+ entry) and a dose-dependent increase in inositol phosphate formation. Pertussis toxin pretreatment did not affect either of these components of the signal transduction pathway but did completely reverse the alpha 2-adrenoceptor-mediated inhibition of forskolin-stimulated cAMP formation. These data indicate that muscarinic regulation of inositol phosphate generation occurs via a pertussis toxin-insensitive G-protein and that Ca2+ entry in these cells may not occur via a G-protein. 相似文献
10.